Welcome to our dedicated page for Albemarle SEC filings (Ticker: ALB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Albemarle Corporation (NYSE: ALB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Virginia-incorporated public company with common stock listed on the NYSE, Albemarle regularly submits reports that cover financial results, material agreements, governance updates and other significant events.
Among the key documents are Form 8-K current reports, where Albemarle discloses items such as quarterly earnings releases, material definitive agreements, goodwill impairment conclusions, director and officer changes, and organizational structure updates. For example, recent 8-K filings have described the company’s third quarter results, the stock purchase agreement related to the sale of a controlling stake in Ketjen’s refining catalyst solutions business, the planned sale of its interest in the Eurecat joint venture, and changes in senior leadership roles.
Investors can also use this page to locate references to Albemarle’s use of proceeds from portfolio transactions, its assessment of impairment charges, and its classification of certain businesses as held for sale. These filings help explain how Albemarle manages its lithium, bromine and catalyst-related operations within its broader financial and strategic framework.
Stock Titan enhances access to Albemarle’s filings by pairing real-time updates from EDGAR with AI-powered summaries that highlight the main points of lengthy documents. Users can quickly understand the implications of new 8-Ks, as well as the content of other core filings such as annual and quarterly reports, and can review disclosures related to executive arrangements and board changes without reading every line of the original text.
Krupa Ander C., identified as an officer (General Counsel & Secretary), reported an insider acquisition in Albemarle Corp (ALB) on 08/06/2025. The Form 4 shows an award of 7,430 restricted stock units (RSUs) granted at a $0 price and reported under transaction code A (acquisition).
The RSUs are described to vest 100% on August 6, 2028 per the award agreement. Following the reported grant the filing shows 11,771 shares beneficially owned by the reporting person. The form is signed by an attorney-in-fact on 08/08/2025.
Krupa Ander C., General Counsel & Secretary of Albemarle Corporation, reported beneficial ownership of 4,341 common shares, consisting of 1,560 issued shares and 2,781 restricted stock units granted across 2023–2025 with staggered vesting through 2028. She also disclosed 2,676 stock options: 1,608 exercisable 02/27/2028 (exp. 02/26/2035) at $78.97 and 1,068 exercisable 02/22/2027 (exp. 02/21/2034) at $118.18. All holdings and vesting terms are reported on Form 3.
Franklin Resources, Inc. and several affiliated investment managers filed Amendment No. 1 to Schedule 13G reporting passive ownership of Albemarle Corporation (ALB) common stock as of 30 June 2025.
The group reports 9,722,191 shares beneficially owned, equal to 8.0 % of ALB’s outstanding shares. Franklin Advisers, Inc. accounts for 8,422,920 shares, including 3,887,547 shares issuable upon debt conversion. Sole voting power covers 9,332,953 shares and sole dispositive power 9,659,698 shares; 62,493 shares are subject to shared voting/disposition, primarily by Templeton Asset Management Ltd.
The filing, made under Rule 13d-1(b), states the holdings are in the ordinary course of business and not intended to influence control. Major individual shareholders Charles B. Johnson and Rupert H. Johnson, Jr. report zero direct ownership. Franklin Income Fund, an advised client, holds 6,475,850 shares (5.3 % of the class). No change-of-control plans, material transactions, or additional events are disclosed.
Albemarle Corporation (ALB) – Form 4 Insider Transaction
Director James J. O’Brien reported two share acquisitions dated 1 July 2025:
- 2,725 common shares granted as the annual installment of non-employee director compensation under the company’s 2023 Stock Compensation and Deferral Election Plan. These shares are scheduled to vest on 1 July 2026.
- 37 common shares issued in lieu of cash dividends that accrued on a prior award granted 1 July 2024 and fully vested on 1 July 2025.
Both transactions were reported with a $0.00 acquisition price, indicating they are equity compensation rather than open-market purchases. Following the two grants, O’Brien’s direct beneficial ownership increased to 8,085 common shares.
No derivative securities were reported and no dispositions occurred. An Exhibit 24 Power of Attorney was filed to authorize the attorney-in-fact signature.
The filing is routine, reflecting scheduled director equity awards rather than discretionary insider buying or selling.